• BEING PATIENT-CENTRIC

BEING PATIENT-CENTRIC

A brand-new, evidence-based, self-evaluation toolkit to support pharma companies become more patient-centric.

PatientView's original Being Patient-Centric toolkit was launched in November 2017. In November and December 2018, PatientView published two supplements to the toolkit, looking at the specific challenges of Being Patient-Centric in Drug Research and Development: from a global perspective, and from a US perspective.
Pricing information can be found at the bottom of this webpage.

Vertical Divider

pv_being_patient-centric_-sample_pages.pdf
File Size:	877 kb
File Type:	pdf

Download File

The groundbreaking November 2017 Being Patient-Centric toolkit analysed 2016-2017 feedback from:

2,000 patient groups worldwide.
Of 50+ different medical specialties.
From 100+ countries.
With international, national, regional, or local geographic remits.

Patient groups describe 9 major attributes that contribute to the process of corporate patient-centricity.
Every one of the attributes is, in turn, shaped by numerous fundamental factors.
For each of the fundamental factors, patient-group comments received by PatientView were reframed in the November 2017 Being Patient-Centric toolkit as questions that the patient groups themselves might well pose to companies. Patient groups pose 139 questions to pharma companies that are seeking to be more patient-centric.

"The new November 2017 self-evaluation toolkit explores the most practical and comprehensive approach I have ever observed across the existing assessment frameworks for patient-centric programmes and initiatives.

Every aspect must be taken into consideration when analysing what a company does to address unmet patient needs, hopes and expectations delivering real value. The industry, patients and community still have a challenge of inconsistency and absence of unified methodology clear for all and easily implementable by several stakeholders.

I believe that the tool will help to identify any gaps/opportunities within engagement with patients as well as caregivers, advocates, activists and members of patient organisations; develop patient-centric strategy and address cross-stakeholder inconsistency."

Dr Oleksandr Gorbenko, ViiV Healthcare

At the end of 2018, PatientView launched two new supplements to its Being Patient-Centric toolkit, focusing on patient/patient-group involvement in R&D from ...
(1) a global perspective, and (2) a US perspective.

Both 2018 supplements are intended to be used in conjunction with PatientView's evidence-based Being Patient-Centric toolkit (published November 2017), which identified nine key attributes of patient centricity.

Why focus on drug R&D?
Pharma's success at one of the nine attributes of patient-centricity, engaging patients in R&D, has consistently been rated as unimpressive by patient groups. PatientView's 2017 Corporate Reputation of Pharma survey (results published April 2018) found that 59% of the 1,300 respondent patient groups thought pharma just "Fair" to "Poor" at engaging patients/patient groups in product research; and 60% thought the same about pharma's record at engaging patients/patient groups in product development. Worldwide, only 13% of patient groups responding to PatientView’s 2017 Corporate Reputation of Pharma survey said that they worked with pharma companies on clinical research, and only 12% said that they worked with pharma on clinical trials.

Patient-centric drug R&D: an area in need of improvement
Pharma's poor performance at engaging patients/patient groups in R&D prompted PatientView to focus further surveys, research, and analysis on the subject during 2018. This activity has led to these two, new, late-2018, in-depth supplements to the original November 2017 Being Patient-Centric toolkit. Both of the 2018 supplements provide companies with evidence-based strategy on the topic of patient-centric drug R&D.

The global perspective: published December 2018 (BPC/#2).
This December 2018 supplement to the November 2017 Being Patient-Centric toolkit takes a deep dive into comments received from 2,000 patient groups worldwide, 2017-2018, on what precisely is needed for companies to be more patient-centric in R&D.
The December 2018 global supplement provides:

A summary of the current global situation on pharma engagement in R&D.
A description of what patient groups expect in terms of their engagement at each of the key stages of R&D, and pharma activities at each of the key stages of R&D.
A list of 128 'prompt' questions posed by these patient groups, aimed at helping companies determine just how patient-centric they are at each of the key stages of R&D.
And a 2018 case study of a patient group as it attempts to be involved with drug R&D.

The US perspective: published November 2018 (BPC/#1).
Since 2016, the Food and Drug Administration (FDA) has been actively promoting programmes which put patients at the heart of drug research and development (R&D), through its 'Patient Focused Drug Development' (PFDD) initiative. Because of the importance of the FDA’s PFDD initiative, and the heightened activity of US patient groups in drug R&D, PatientView decided to conduct a survey of patient groups in the US on the subject. The survey ran August-October 2018, and this November 2018 supplement (and its Appendix) contains the survey’s results.

The US study's 104 respondent US patient groups were asked about four important topics: (1) How patient groups define patient-centric R&D. (2) Their views on the FDA's PFDD. (3) Their views on pharma's performance at being patient centric in R&D. And (4) their views on the role of 'real-world' evidence versus clinical trials.
The November 2018 US supplement and its Appendix analyse the opinions of all 104 respondent US patient groups, and, more specifically, the responses from respondent US patient groups specialising in cancer, rare diseases, and neurological conditions.

appendix_usa_pfdd_survey_-_sample_pages.pdf
File Size:	698 kb
File Type:	pdf

Download File

bpc_us_2018_pfdd_survey_-_sample_pages.pdf
File Size:	907 kb
File Type:	pdf

Download File

PRICING:
The Being Patient-Centric package consists of three items: (1.) the November 2017 Being Patient-Centric toolkit; (2.) the November 2018 US supplement, entitled US Patient-Group Perspectives on Patient-Centric R&D; and (3.) the December 2018 global supplement, The Opinions of Patient Groups Worldwide on Patient Engagement in Drug R&D.

Each of the above three Being Patient-Centric items, purchased individually, is priced at GBP 6,000.
Any two of the above three items, purchased together: GBP 9,000.
All three of the above items, purchased together: GBP 12,000.